Wall Street brokerages forecast that Aethlon Medical, Inc. (NASDAQ:AEMD – Get Rating) will report $1.02 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Aethlon Medical’s earnings, with the highest sales estimate coming in at $2.00 million and the lowest estimate coming in at $40,000.00. Aethlon Medical reported sales of $30,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 3,300%. The company is expected to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Aethlon Medical will report full-year sales of $1.46 million for the current fiscal year, with estimates ranging from $320,000.00 to $2.60 million. For the next year, analysts expect that the business will post sales of $0.00. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Aethlon Medical.
Aethlon Medical (NASDAQ:AEMD – Get Rating) last released its quarterly earnings results on Monday, February 14th. The medical equipment provider reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.26 million. Aethlon Medical had a negative return on equity of 45.91% and a negative net margin of 2,823.49%. During the same period in the previous year, the firm posted ($0.20) earnings per share.
AEMD has been the topic of several research analyst reports. StockNews.com initiated coverage on Aethlon Medical in a research note on Monday, April 11th. They set a “sell” rating on the stock. Maxim Group dropped their price target on Aethlon Medical from $11.00 to $4.00 in a research note on Tuesday, February 15th.
NASDAQ:AEMD traded down $0.06 during mid-day trading on Wednesday, hitting $1.24. 22,236 shares of the company’s stock traded hands, compared to its average volume of 51,712. The company has a fifty day moving average of $1.36 and a 200 day moving average of $2.13. Aethlon Medical has a twelve month low of $1.12 and a twelve month high of $12.49.
Several large investors have recently bought and sold shares of AEMD. Renaissance Technologies LLC increased its holdings in shares of Aethlon Medical by 377.0% in the fourth quarter. Renaissance Technologies LLC now owns 242,200 shares of the medical equipment provider’s stock valued at $450,000 after purchasing an additional 191,425 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in Aethlon Medical in the third quarter worth approximately $397,000. BlackRock Inc. grew its position in Aethlon Medical by 771.7% in the third quarter. BlackRock Inc. now owns 73,074 shares of the medical equipment provider’s stock worth $282,000 after acquiring an additional 64,691 shares during the period. Geode Capital Management LLC grew its position in Aethlon Medical by 32.3% in the third quarter. Geode Capital Management LLC now owns 136,451 shares of the medical equipment provider’s stock worth $526,000 after acquiring an additional 33,330 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in Aethlon Medical in the third quarter worth approximately $111,000. 7.71% of the stock is owned by hedge funds and other institutional investors.
Aethlon Medical Company Profile (Get Rating)
Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
Receive News & Ratings for Aethlon Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aethlon Medical and related companies with MarketBeat.com’s FREE daily email newsletter.